Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer by Igor Makhlin, Nicholas P. McAndrew, E. Paul Wileyto, Amy S. Clark, Robin Holmes, Lisa N. Bottalico, Clementina Mesaros, Ian A. Blair, Grace R. Jeschke, Kevin R. Fox, Susan M. Domchek, Jennifer M. Matro, Angela R. Bradbury, Michael D. Feldman, Elizabeth O. Hexner, Jacqueline F. Bromberg, Angela DeMichele

Get full text